Anthos Therapeutics

Anthos Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on developing innovative therapies for cardiovascular and metabolic diseases. Founded in 2018, the company specializes in treatments targeting Factor XI and XIa, essential components of the intrinsic coagulation pathway. Its lead product, MAA868, is an antibody designed to provide an anti-thrombotic effect, allowing healthcare professionals to prevent various thrombotic diseases while minimizing the risk of bleeding. By advancing long-acting treatment options, Anthos Therapeutics aims to improve care for patients suffering from cardiovascular conditions, representing a significant advancement over conventional therapies.

David McIntyre

CFO

Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.